INCY
DependentIncyte
$95.55
-0.55%
as of 13 Apr
Power Core
Moat in one sentence: Incyte's moat is its first-mover dominance in selective JAK1/JAK2 inhibition for myeloproliferative neoplasms, reinforced by physician entrenchment, real-world evidence accumulation, and regulatory exclusivities that create a switching-cost barrier for a patient population with limited therapeutic alternatives.
Direction of Movement
Lateral with Mounting Downward Pressure on the Horizon
ROC 200
+34.7%
INCY
Incyte
$95.55
-0.55%
as of 13 Apr
DCF Fair Value: $121.35
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics targeting hematology, oncology, inflammation, and autoimmunity. Its portfolio features key products such as JAKAFI (ruxolitinib), approved for intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; OPZELURA, addressing atopic dermatitis and vitiligo in the dermatology segment; and MONJUVI/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma. Additional offerings include PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor, alongside NIKTIMVO, ZYNYZ, and ICLUSIG, contributing to its expanding hematology and oncology segments. Incyte Corporation also generates royalty revenues from partnered products like Jakavi and Olumiant. The company operates across the United States, Europe, Canada, and Japan, advancing a pipeline of candidates in oncology and immunology to address unmet medical needs. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte Corporation plays a significant role in delivering targeted therapies for complex diseases.